Macroaxis LLC’s Post

$ENVB - Still bullish? Upcoming quarterly report is on 1st of April 2024.: About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enveric Biosciences recorded a loss per share of 11.51. The entity last dividend was issued on the 23rd of April 2008. The firm had 1:50 split on the 15th of July 2022. https://lnkd.in/gc9bm5qP #stocks #stocktwits #thematic_portfolio

$SCNI - Symbol was changed from BVXV on 7th of September 2023.: About 24.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Scinai Immunotherapeutics recorded a loss per share of 4.4. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 25th of November 2022. https://lnkd.in/gRcSyu6W #stocks #stocktwits #thematic_portfolio

$BIOV - 10 for 1 Split on the 24th of December can drive Bio View to bounce back: About 52.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio-View last dividend was issued on the 22nd of March 2017. The entity had 10:1 split on the 7th of October 2023. https://lnkd.in/gqJw9waK #stocks #stocktwits #thematic_portfolio

$VBLT - Still bullish on Vascular Biogenics? Symbol renaming on the 17th of October 2023 can force Vascular Biogenics to rebound: About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.35. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vascular Biogenics recorded a loss per share of 0.18. The entity had not issued any dividends in recent years. https://lnkd.in/g5MwAJGc #stocks #stocktwits #thematic_portfolio

$VBLT - Maintains -0.1312 Information Ratio. Symbol was renamed to NTBL on 17th of October 2023: About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.35. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vascular Biogenics recorded a loss per share of 0.18. The entity had not issued any dividends in recent years. https://lnkd.in/gV2r9haX #stocks #stocktwits #thematic_portfolio

$BIOV - 10 for 1 Split on the 24th of December can drive Bio View to come-back: About 52.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio-View last dividend was issued on the 22nd of March 2017. The entity had 10:1 split on the 18th of November 2023. https://lnkd.in/gFfA4gi3 #stocks #stocktwits #thematic_portfolio

$QIA - 25 for 24 Split can cause some disturbance for QIAGEN NV: About 72.0% of the company shares are owned by institutional investors. The book value of QIAGEN NV was at this time reported as 15.22. The company had not issued any dividends in recent years. QIAGEN NV had 25:24 split on the 8th of December 2023. #stocks #stocktwits #thematic_portfolio

$SCNI - Upcoming quarterly report will be on 15th of April 2024.: About 24.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Scinai Immunotherapeutics recorded a loss per share of 4.4. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 25th of November 2022. https://lnkd.in/g_tvu6eT #stocks #stocktwits #thematic_portfolio

$BIOV - 10 for 1 Split can cause some disturbance for Bio View: About 52.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio-View last dividend was issued on the 22nd of March 2017. The entity had 10:1 split on the 14th of December 2023. https://lnkd.in/gEc_8VVH #stocks #stocktwits #thematic_portfolio

$KMPH - Analysis of KemPharm Symbol renaming on the 1st of March can force KemPharm to slide back: About 18.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. KemPharm recorded a loss per share of 0.91. The entity last dividend was issued on the 28th of December 2020. The firm had 1:16 split on the 28th of December 2020. https://lnkd.in/gn6A6hQC #stocks #stocktwits #thematic_portfolio